Quantcast

Latest Zinc finger nuclease Stories

2014-07-29 12:35:05

The CRISPR/Cas9 system enables accurate and efficient genetic engineering. ST. LOUIS, July 29, 2014 /PRNewswire/ -- SAGE Labs Inc., a leading provider of products, services and technologies in the field of genome engineering, announced today that they have licensed CRISPR/Cas9 technology from the Broad Institute. The license enables SAGE Labs to use the CRISPR/Cas9 system to engineer cell and animal models for their clients as well as distribute validated CRISPR reagents. This is the...

2014-07-07 12:28:43

CRISPR/Cas9 system allows researchers to quickly and precisely edit DNA ST. LOUIS, July 7, 2014 /PRNewswire/ -- SAGE Labs Inc., a leading provider of in vivo products, services and technologies in the field of genome engineering, today launched its SAGEspeed CRISPR/Cas9 Reagents. These reagents enable researchers to quickly and easily perform genetic engineering in animal models, such as mice and rats, as well as cell lines. Since 2009, SAGE Labs has been using targeted nucleases,...

2014-05-30 08:24:46

First Clinical Application of Genome Editing Technology in Hematopoietic Stem/Progenitor Cells RICHMOND, Calif., May 30, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that the California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of Sangamo's zinc finger nuclease (ZFN)...

2014-05-28 16:26:41

Groundbreaking Nature Publication Describes Successful ZFN Driven Genome Editing in Long-Term Repopulating Stem Cells Necessary for Clinical Translation RICHMOND, Calif., May 28, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the publication in Nature of data demonstrating efficient zinc finger nuclease (ZFN)-mediated, targeted gene insertion that resulted in correction of the genetic defect in stem cells from an individual with X-linked severe combined...

2014-05-27 08:28:00

SB-728-T-Treated Subject Maintains Control of Viral Load for 45 Weeks Without Anti-Retroviral Drugs RICHMOND, Calif., May 27, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics(®) were outlined in several presentations and posters at the 17th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) from May 21-24, 2014....

2014-05-14 08:31:21

RICHMOND, Calif., May 14, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics(®) will be presented at the 17th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Fourteen oral and poster presentations, given by Sangamo scientists and their academic collaborators, will detail data from Sangamo's therapeutic and research programs...

2014-05-06 16:32:43

Partnership with Biogen Idec and Recent Follow-on Financing Enhance Cash Position RICHMOND, Calif., May 6, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2014 financial results and accomplishments. http://photos.prnewswire.com/prnvar/20130102/SF35903LOGO For the first quarter ended March 31, 2014, Sangamo reported a consolidated net loss of $7.6 million, or $0.12 per share, compared to a net loss of $6.9 million, or $0.13 per share, for the same...

2014-05-06 08:33:26

Innovative paired-nickase design provides breakthrough that minimizes off-target effects to accelerate genetic research ST. LOUIS, May 6, 2014 /PRNewswire/ -- Sigma-Aldrich Corporation (Nasdaq: SIAL) today announced the availability of high-fidelity Sigma(®) CRISPR paired nickases, a novel patent-pending gene editing tool that can be easily and inexpensively employed in academic, agricultural, pharmaceutical, human health and other applications. The high-fidelity CRISPR technology...

2014-04-28 10:17:33

A next-generation genome editing system developed by Massachusetts General Hospital (MGH) investigators substantially decreases the risk of producing unwanted, off-target gene mutations. In a paper receiving online publication in Nature Biotechnology, the researchers report a new CRISPR-based RNA-guided nuclease technology that uses two guide RNAs, significantly reducing the chance of cutting through DNA strands at mismatched sites. "This system combines the ease of use of the widely...

2014-03-06 12:28:29

Company Outlines Future Plans for HIV "Functional Cure" RICHMOND, Calif., March 6, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the presentation of data from its SB-728-T program to develop a 'functional cure' for HIV/AIDS at the Conference on Retroviruses and Opportunistic Infections (CROI 2014). The conference is being held in Boston from March 3 to 6, 2014. Data from an earlier Phase 1 clinical study in this program were also published in the March 6,...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related